Mer­ck KGaA rais­es aware­ness for smol­der­ing MS symp­toms that cause pa­tients to 'un­rav­el'

Re­cent ev­i­dence sug­gests re­duc­ing re­laps­es is “on­ly part of [the] bat­tle” for mul­ti­ple scle­ro­sis pa­tients, ac­cord­ing to Mer­ck KGaA.

While it was pre­vi­ous­ly thought that MS pa­tients go in­to pe­ri­ods of re­mis­sion, sci­ence now points to some pa­tients ex­pe­ri­enc­ing grad­ual neu­rode­gen­er­a­tion from the start, caus­ing them to sub­tly wors­en de­spite no signs of re­lapse. Mer­ck KGaA’s EMD Serono wants to dri­ve aware­ness to the con­di­tion, called “smol­der­ing MS,” as it ad­vances its late-stage BTK in­hibitor evo­bru­ti­nib in re­laps­ing MS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER